rss
Eur J Hosp Pharm 20:A219-A220 doi:10.1136/ejhpharm-2013-000276.608
  • Clinical pharmacy and clinical trials (including case series)

CPC-151 Type of Cancer and Risk Factors in HIV Patients on Antiretroviral Treatment

  1. RM Catalá
  1. Hospital Universitario de Mostoles, Pharmacy, Mostoles (Madrid), Spain

Abstract

Background HIV infection is associated with increased risk of cancer:

  1. AIDS-defining cancers (ADC): Kaposi’s sarcoma (KS), non-Hodgkin lymphoma (NHL), cervix cancer.

  2. non-AIDS-defining cancers (NADC): Hodgkin lymphoma (HL), anal cancer, lung, head, neck, hepatocarcinoma.

Purpose To analyse patients with antiretroviral therapy and chemotherapy, type of cancer and associated risk factors.

Materials and Methods Descriptive study of patients with antiretroviral and chemotherapy between 2004–2011, extracting data from medical records and the Farmatools programme, analysing using SPSS 11.0.

Results 33 patients were obtained (3.7% of all HIV patients on antiretroviral treatment); 82% men: 16 with ADC (11 NHL, 3 KS, and 2 with NHL and KS) and 17 with NADC (5 HL, 3 lung cancer, 3 head-neck, 3 anal, 1 ovary, 1 gastric and 1 chronic lymphocytic leukaemia). When cancer was diagnosed patients presented: CD4<200 cells/microliter (27.3%), detectable viral load (VL) (33.3%), C3 category (63.6%), smokers (63.6%), human papillomavirus (HPV) (6.1%), Epstein Barr virus (21.2%), human herpes virus 8 (HHV8)(21.2%), hepatitis B-C (48.5%), intravenous drug addict (24.2%). 8 patients died.

80% KS patients and 66.7% head-neck cancer had CD4<200 (P = 0.036). 62.5% of those who died presented CD4<200 (P = 0.009). 66.6% of anal cancer patients presented HPV (P = 0.006). 100% of KS presented HHV8 (P = 0.002).

Conclusions 3.7% of HIV patients on treatment developed neoplasms, more than 50% were NADC, of which 88% started in patients with an undetectable VL, confirming a nice immunological status when cancer was diagnosed.

No conflict of interest.

EJHP blog

Analysis and discussion of the latest news, research findings and policy developments in hospital pharmacy.

Visit the blog >>

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EJHP.

View free sample issue >>

Email alerts

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article